Showing 1871-1880 of 8179 results for "".
Dr. Ross Discusses Experience with Gemini Laser
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/dr-ross-discusses-experience-with-gemini-laser/19470/“There are a lot of new technologies out there, but one of the tried-and-true technologies is KTP laser and the long-pulse YAG laser. And the Gemini fits the bill for both of those wavelengths. So in a sense the Gemini is a time-tested product. It has served us well at our clinic, both at the NavyPart 6, 1726 nm lasers: Growing the market for the 1726 nm wavelength lasers
https://practicaldermatology.com/series/scientifically-speaking/1726-nm-lasers-five-dermatologists-discuss-the-lasers-benefits-and-drawbacks-for-treating-acne-and-other-skin-conditions/24344/Chapter 6 of 7: David Goldberg, MD, from New York, Emil Tanghetti, MD, from Sacramento, Jordan Wang, MD, from Philadelphia and New York and Naz Saedi, MD, from Philadelphia talk about the growing the market for the 1726 nm wavelength lasers.ISDPA: Dr. Bhatia on JAK Inhibitors
https://practicaldermatology.com/conferences/isdpa-midwest-derm-2024/isdpa-dr-bhatia-jak-inhibitors/27064/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, talks about his presentation on JAK inhibitors at the Illinois Society of Dermatology Physician Assistants (ISDPA) Midwest Dermatology Conference 2024.The Benefits of Balneotherapy for Atopic Dermatitis
https://practicaldermatology.com/programs/practical-dermatology-type-ii-inflammation-journal-club/the-benefits-of-balneotherapy-for-atopic-dermatitis/39776/Practical Dermatology editorial board member Peter Lio, MD, and Karan Lal, DO, MS, FAAD, discuss the use of balneotherapy as an adjunctive treatment for dermatologic diseases, including an International Journal of Biometeorology article titled, “Balneotherapy using thermal mineral water baths and deEvaluating Lebrikizumab in Pigmented Skin
https://practicaldermatology.com/videos/updates-atopic-dermatitis/evaluating-lebrikizumab-in-pigmented-skin/36490/Andrew Alexis, MD, MPH, discusses new data presented at the Revolutionizing Atopic Dermatitis (RAD) Conference from the phase 3b Admirable trial, the first dedicated study for evaluating the efficacy and safety of Lilly's FDA-approved medicine in adult and adolescent patients with pigmented skin andOrigins of AD: Recent Advances
https://practicaldermatology.com/issues/april-2025/origins-of-ad-recent-advances/35586/This paper reviews a study by Yadev et al. and further investigates the role of transient receptor potential ankyrin 1 (TRPA1) in the pathogenesis of atopic dermatitis (AD).New Hope for Patients with Onychomycosis
https://practicaldermatology.com/issues/practicaldermatology-com-march-2025/new-hope-for-patients-with-onychomycosis/33161/Onychomycosis, a non-self-healing fungal infection of the toenails or fingernails, is a common infection accounting for 20% of all nail diseases in adults, affecting 5% of the worldwide population.What's New in Atopic Dermatitis?
https://practicaldermatology.com/programs/practical-dermatology/whats-new-in-atopic-dermatitis/33014/Emma Guttman, MD, PhD, professor and chair of dermatology at Mount Sinai, talks about the latest developments in treatments and therapies for atopic dermatitis.In-Depth From the Science of Skincare Summit
https://practicaldermatology.com/issues/january-february-2025/in-depth-from-the-science-of-skincare-summit/32979/The 2024 Science of Skincare Summit this past November again positioned itself as a pivotal event in the dermatology field, offering groundbreaking insights into the intersection of innovation, consumer trends, and evidence-based skincare. Take a closer look at some of the research.Analysis Evaluates Risks of Cardiovascular Events Among Biologics for Psoriatic Diseases
https://practicaldermatology.com/series/dermwire-tv/analysis-evaluates-risks-of-cardiovascular-events-among-biologics-for-psoriatic-diseases/32412/In this week's DermwireTV, a new analysis evaluates the risks of major adverse cardiovascular events among patients treated with biologics for psoriatic diseases; a phase 3 clinical trial examines the use of nemolizumab in adults with prurigo nodularis; and the president of Journey Medical discusses